TUCSON, Ariz.--(BUSINESS WIRE)--Although the CardioWest™ temporary Total Artificial Heart (TAH-t) was designed, engineered and is privately owned and manufactured in the United States, it is the Europeans who are being discharged to recover at home while Americans with the TAH-t are confined to the hospital. These patients are waiting for donor hearts for transplant. Since the start of the 2003 clinical study of the portable driver, stable patients in Europe have been discharged to recover at home. The driver provides precisely calibrated pulses of air that power the TAH-t. The portable driver received the CE mark for use throughout Europe on July 17, 2006.
